In some cancers, even if cancer cells are immunogenic, they are also identified to have many receptors (e.g., PD-L1, PD-L2) to stimulate immune checkpoint targets (e.g., PD-1) and block the immune response. This evidence concerns the gene PDCD1LG2 and cancer.